The draft updated guidance on assessing and preventing falls in older people and people aged 50 and over at higher risk opens ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) TA1006 12 September 2024 12 September 2024 Evinacumab for treating homozygous familial hypercholesterolaemia ...

All NICE products on vulnerable groups. Includes any guidance and quality standards.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Roche (mycophenolate mofetil, rituximab) – confidentiality agreement not signed, not participating Sandoz (methotrexate, mycophenolate mofetil, rituximab) – confidentiality agreement not signed, not ...

For the first time, NICE has recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce the risk of the disease coming back. NICE ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

All NICE products on COVID-19. Includes any guidance and advice.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.